Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박시훈 | - |
dc.date.accessioned | 2016-08-28T11:08:43Z | - |
dc.date.available | 2016-08-28T11:08:43Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 1175-3277 | - |
dc.identifier.other | OAK-13771 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/229723 | - |
dc.description.abstract | Background: Despite recommendations for more intensive treatment and the availability of several effective treatments, hypertension remains uncontrolled in many patients. Objective: The aim of this study was to determine the dose-response relationship and assess the efficacy and safety of amlodipine or losartan monotherapy and amlodipine camsylate/losartan combination therapy in patients with essential hypertension. Methods: This was an 8-week, randomized, double-blind, factorial design, phase II, multicenter study conducted in outpatient hospital clinics among adult patients aged 18-75 years with essential hypertension. At screening, patients received placebo for 2-4 weeks. Eligible patients (n = 320) were randomized to one of eight treatment groups: amlodipine 5mg or 10 mg, losartan 50mg or 100 mg, amlodipine camsylate/losartan 5mg/50 mg, 5mg/100 mg, 10 mg/50 mg, or 10 mg/100 mg. Main Outcome Measures: The assumption of strict superiority was estimated using the mean change in sitting diastolic blood pressure (DBP) at 8 weeks. Safety was monitored through physical examinations, vital signs, laboratory test results, ECG, and adverse events. Results: The reduction in DBP at 8 weeks was significantly greater in patients treated with the combination therapies compared with the respective monotherapies for all specified comparisons except amlodipine camsylate/losartan 10 mg/100mg versus amlodipine 10 mg. The incidence of adverse events in the group of patients treated with the amlodipine camsylate/losartan 10 mg/50 mg combination tended to be higher than for any other group (27.9%, 12/43); however, the effect was not statistically significant. Conclusion: Combination amlodipine camsylate/losartan (5 mg/50 mg, 5mg/100mg and 10 mg/50 mg) resulted in significantly greater BP lowering compared with amlodipine or losartan monotherapy, and was determined to be generally safe and tolerable in patients with essential hypertension. © 2012 Adis Data Information BV. All rights reserved. | - |
dc.language | English | - |
dc.title | Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: An 8-week, randomized, double-blind, factorial, phase II, multicenter study | - |
dc.type | Article | - |
dc.relation.issue | 1 | - |
dc.relation.volume | 12 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | 35 | - |
dc.relation.lastpage | 47 | - |
dc.relation.journaltitle | American Journal of Cardiovascular Drugs | - |
dc.identifier.doi | 10.2165/11597170-000000000-00000 | - |
dc.identifier.wosid | WOS:000301278100004 | - |
dc.identifier.scopusid | 2-s2.0-84863023379 | - |
dc.author.google | Park C.-G. | - |
dc.author.google | Youn H.-J. | - |
dc.author.google | Chae S.-C. | - |
dc.author.google | Yang J.-Y. | - |
dc.author.google | Kim M.-H. | - |
dc.author.google | Hong T.-J. | - |
dc.author.google | Kim C.H. | - |
dc.author.google | Kim J.J. | - |
dc.author.google | Hong B.-K. | - |
dc.author.google | Jeong J.-W. | - |
dc.author.google | Park S.-H. | - |
dc.author.google | Kwan J. | - |
dc.author.google | Choi Y.-J. | - |
dc.author.google | Cho S.-Y. | - |
dc.contributor.scopusid | 박시훈(9737584900;57191750840) | - |
dc.date.modifydate | 20221123115020 | - |